High Purity Fast Delivery Pharmaceutical Intermediate Anti Cancer Lapatinib CAS 231277-92-2

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Model NO.: 231277-92-2
• Other Name: Tykerb
• CAS: 231277-92-2
• Sample: Available
• Delivery Time: Prompt Delivery
• Shipping Time: 12-15 Workdays
• Package Size: 100g/1kg/25kg
• Usage: Anti Cancer
• Transport Package: Bottle, Can, Drum, Plastic Container, Vacuum Packe
• Specification: powder
• Trademark: Senwayer
• Origin: Wuhan, China
• HS Code: 0000000000
• Production Capacity: 2000 Kilograms Per Month

Product Description

High Purity Fast Delivery Pharmaceutical Intermediate Anti Cancer Lapatinib CAS 231277-92-2

Name: Lapatinib
English synonym: Tykerb
CAS Number: 231277-92-2
Molecular formula: C29H26ClFN4O4S
Molecular weight: 581.06
EINECS number: 1806241-263-5

Boiling point: 750.7±60.0°C(Predicted)
Density: 1.381±0.06g/cm3(Predicted)
Storage conditions: Keep in dark place, Sealed in dry, 2-8°C
Acidity coefficient (pKa): 6.34±0.19(Predicted)

Lapatinib is an oral reversible small molecule tyrosine kinase inhibitor targeting HER-1/HER-2. Lapatinib has a different mechanism of action than the humanized monoclonal antibody drug Herceptin that has been approved for marketing. It can down-regulate cell proliferation signals by double-blocking the HER-1/HER-2 pathway. The clinical indication is the combination of capecitabine in the treatment of advanced or metastatic breast cancer with overexpression of HER2 and previous treatments including anthracyclines, taxanes and trastuzumab. The effective rate of advanced first-line monotherapy is about 12~24%, general clinical guidelines recommend second-line medication, and the effective rate of combined treatment with capecitabine is about 26~33%, and the clinical benefit rate is as high as 71.3%, which is also the most commonly used Of lapatinib combined with chemotherapy.